Back to search

Article

Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis

2020-06-11

Abstract excerpt

Non-alcoholic steatohepatitis (NASH) is a common chronic liver disease that causes worldwide morbidity and mortality, yet there is still a lack of pharmacological therapies. Liver inflammation is an important contributor for disease progression from non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH). We identified HDAC inhibitor givinostat as a potent inhibitor of macrophages inflamm...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
13dcbb70-7135-56fb-b122-967535b91eb1
DOI
10.1101/2020.06.09.141655
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosisDOI 10.1101/2020.06.09.141655
Multiomics analyses decipher intricate changes in the cellular and metabolic landscape of steatotic livers upon dietary restriction and sleeve gastrectomySemantic proximity
Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARαSemantic proximity
Modulation of metabolic, inflammatory, fibrotic and cell death pathways by Resmetirom in metabolic dysfunction-associated steatohepatitis (MASH): A transcriptomic profiling studySemantic proximity
Inhibition of histone methyltransferase G9a aggravates phenotypic severity of hepatic lipotoxicity in non-alcoholic steatohepatitis (NASH).Semantic proximity
Tirzepatide but not Semaglutide Ameliorates Hepatic Steatosis and Inflammatory Infiltration in a Mouse Model of MASLD via Inhibition of the CCL2/CCR2-PI3K-Akt PathwaySemantic proximity
The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH modelSemantic proximity
Osteoprotegerin deficiency aggravates methionine- choline- deficient diet-induced nonalcoholic steatohepatitis in miceSemantic proximity
Hepatocyte-Targeted siTAZ Therapy Lowers Liver Fibrosis in NASH Diet-Fed Chimeric Mice with Hepatocyte-Humanized LiversSemantic proximity
Combined Metabolic Activators decrease liver steatosis by activating mitochondrial metabolism in a Golden Syrian hamster studySemantic proximity
Western diet induces severe nonalcoholic steatohepatitis, ductular reaction, and hepatic fibrosis in liver CGI-58 knockout mice.Semantic proximity
GCN5 drives NAFLD progression through LXRα/SREBP1c signaling pathway-mediated de novo lipogenesisSemantic proximity
An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitisSemantic proximity
Select a neighboring publication to make it the new centre.